Tekmira to Present at Jefferies 2015 Healthcare Conference
May 21 2015 - 5:00PM
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR), a
biopharmaceutical company dedicated to discovering, developing and
commercializing a cure for patients suffering from chronic
hepatitis B infection (HBV), today announced that Dr. Mark Murray,
Tekmira's President and CEO, will present a corporate update at the
Jefferies 2015 Healthcare Conference on Tuesday, June 2, 2015 at
12.30pm – 1.00pm (PT) / 3.30pm-4.00pm (ET) in New York.
Webcast Information
A live webcast of the presentation can be accessed through the
Investor Section of Tekmira's website at www.tekmira.com. A webcast
replay of the presentation will be available on the Tekmira website
following the event.
About Tekmira
Tekmira Pharmaceuticals Corporation is a biopharmaceutical
company dedicated to discovering, developing and commercializing a
cure for patients suffering from chronic hepatitis B infection
(HBV). Our strategy is to target the three pillars necessary to
develop a curative regimen for HBV, including suppressing HBV
replication within liver cells, stimulating and reactivating the
body's immune system so that it can mount an effective defense
against the virus and, most importantly, eliminating the reservoir
of viral genomic material known as covalently closed circular DNA,
or cccDNA, that is the source of HBV persistence. Our portfolio of
assets includes eight drug candidates for use in combination to
develop a cure for HBV, and includes our product TKM-HBV currently
in Phase 1 clinical studies.
We are also developing a pipeline of oncology, anti-viral and
metabolic therapeutics that leverage our expertise in RNA
interference (RNAi) therapeutics and leading Lipid Nanoparticle
(LNP) technology. RNAi and LNP technology have the potential to
generate new therapeutics that take advantage of the body's own
natural processes to silence disease causing genes, or more
specifically, to eliminate specific gene-products, from the cell.
We intend to continue the clinical development of TKM-PLK1 for
advanced gastrointestinal neuroendocrine tumors, adrenocortical
carcinoma and hepatocellular carcinoma; and TKM-Ebola, and
TKM-Ebola-Guinea for ebola virus disease. Our metabolic programs
and TKM-Marburg are in pre-clinical development.
With a proven management team and scientific leadership in
antiviral and RNAi drug discovery and development, we are
developing a robust pipeline of products with the goal of
optimizing value for our shareholders and partners, and to serve
patients worldwide. Tekmira is headquartered in Vancouver, BC,
Canada with offices in Doylestown, PA, USA. For more information,
visit www.tekmira.com.
CONTACT: Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email:acutler@tekmira.com
Julie P. Rezler
Director, Investor Relations
Phone: 604.419.3200
Email: jrezler@tekmira.com
Media
Please direct all media inquiries to: media@tekmira.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Apr 2023 to Apr 2024